[High-dose omega-3 fatty acid supplementation in patients with persistent allergic rhinitis sensitized to perennial allergens: a randomized, placebo-controlled clinical trial].

High-dose omega-3 fatty acid supplementation did not significantly improve quality of life scores compared to placebo in patients with persistent allergic rhinitis.

• After the intervention, median quality of life scores were similar between the experimental and control groups (p = 0.668).
• The experimental group received EPA 1340 mg and DHA 924 mg daily for 2 months.
• Both groups also received intranasal fluticasone and allergy immunotherapy during the escalation phase.
• The experimental group included 10 patients (2 men, 8 women) with a mean age of 31.5 ± 15.1 years.

High-dose omega-3 fatty acid supplementation did not significantly reduce nasal symptom severity scores compared to placebo.

• After the intervention, median nasal symptom scores were similar between both groups (p = 0.920).
• The control group included 12 patients (5 men, 7 women) with a mean age of 27.4 ± 14.3 years.
• Age was not significantly different between the two groups (p = 0.56).
• Both groups received pharmacological treatment with intranasal fluticasone and allergy immunotherapy as background therapy.

High-dose EPA and DHA supplementation was found to be safe in patients with persistent allergic rhinitis sensitized to perennial allergens.

• The study was a randomized, double-blind, placebo-controlled design.
• The intervention lasted 2 months with daily doses of EPA 1340 mg and DHA 924 mg.
• No safety concerns were reported for the supplementation regimen.
• The study population consisted of patients sensitized to perennial allergens with persistent allergic rhinitis.

The study enrolled a small total sample of 22 patients across both treatment groups.

• The experimental group comprised 10 patients and the control group comprised 12 patients.
• The experimental group had 2 men and 8 women; the control group had 5 men and 7 women.
• Mean age was 31.5 ± 15.1 years in the experimental group and 27.4 ± 14.3 years in the control group.
• The authors noted that further clinical trials are required to clarify omega-3's potential role as an adjunctive strategy.